MedinCell announces participation in the Jefferies London Healthcare Conference 2021
October 25, 2021
Previous PostPhase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: - Prolonged time to impending relapse - Decreased risk of relapse - Increased chance of clinical stability
Next PostMedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021